Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy

NCT07340164 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

116

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer
Ovarian Carcinoma, Recurrent
Ovarian Cancer Metastatic Recurrent
Ovarian Cancer (OvCa)

Interventions

DRUG: Trastzumab Deruxtecan
DRUG: Bevacizumab
DRUG: Platinum Based Chemotherapy

Sponsor

Yonsei University

Collaborators

[object Object]
[object Object]